Figure 1b:

Flowcharts show study design of CCR2 imaging with ECL1i peptide. (a) Peptide labeling and stability. (b) Mouse imaging studies. The number of mice in each treatment group is indicated. Bold boxes indicate in vivo PET/CT studies. Time-activity analysis was performed on a subgroup of PET images obtained 24 hours after treatment. (c) Human lung tissue studies. A subgroup of lung tissues from subjects with COPD displaying elevated levels of CCR2-positive cells was analyzed for copper 64 (⁶⁴Cu)–tetraazacyclododecane tetraacetic acid (DOTA)–ECL1i binding by using autoradiography followed by blocking (n = 6).